0000000000140785

AUTHOR

Timothy Hardy

showing 3 related works from this author

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

2020

© 2020 The Author(s).

Liver CirrhosisPROGNOSISCirrhosisSCORING SYSTEM[SDV]Life Sciences [q-bio]PROGRESSIONDiseaseBiomarker Cirrhosis NAFLD NASHSTEATOHEPATITISDEFINITIONSCohort Studies0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasePharmacology (medical)030212 general & internal medicineLongitudinal StudiesRegistriesComputingMilieux_MISCELLANEOUSmedia_commonPharmacology. TherapyFatty liverLiver NeoplasmsNASHGeneral Medicine3. Good healthCirrhosisLiver317 PharmacyCohort0305 other medical scienceCohort studymedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAGeriatrikQUESTIONNAIRENAFLD; NASH; Cirrhosis; Biomarker610 Medicine & health03 medical and health sciencesNAFLDmedicineSTEATOSISmedia_common.cataloged_instanceHumansALGORITHMEuropean unionIntensive care medicine030505 public healthbusiness.industryCONSUMPTIONBiomarkerSTAGING SYSTEMmedicine.diseaseDiabetes Mellitus Type 2Geriatrics3121 General medicine internal medicine and other clinical medicine3111 BiomedicineHuman medicineSteatohepatitisbusinessBiomarker; Cirrhosis; NAFLD; NASH
researchProduct

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

2022

Background & Aims Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile miRNAs comprehensively at all NAFLD stages. Methods We profiled 2,083 serum miRNAs in a discovery cohort (183 cases with NAFLD representing the complete NAFLD spectrum and 10 population controls). miRNA libraries generated by HTG EdgeSeq were sequenced by Illumina NextSeq. Selected serum miRNAs were profiled in 372 additional cases with NAFLD and 15 population controls by quantitative reverse transcriptase PCR. Results Levels of 275 miRNAs differed between cases and population controls. Fewer differences were seen wi…

SCORING SYSTEMCPM counts per millionAUROC area under the receiver operating characteristicRC799-869AST aspartate aminotransferaseMicroRNA; Non-alcoholic fatty liver disease; Biomarker; SequencingTGF-β transforming growth factor-betaGastroenterologySTEATOHEPATITISLiver disease0302 clinical medicineFibrosismiRNA microRNAlogFC log2 fold changeFIBROSISImmunology and AllergySequencing0303 health scienceseducation.field_of_studyNAS NAFLD activity scoremedicine.diagnostic_testFatty liverGastroenterologyGTEx Genotype-Tissue ExpressionMicroRNADiseases of the digestive system. Gastroenterology3. Good healthReal-time polymerase chain reactionBiomarker MicroRNA Non-alcoholic fatty liver disease SequencingLiver biopsyACIDBiomarker (medicine)030211 gastroenterology & hepatologyLife Sciences & BiomedicineResearch ArticleEXPRESSIONmedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseNASH non-alcoholic steatohepatitisPopulationGastroenterology and HepatologySAF steatosis–activity–fibrosisVALIDATIONER endoplasmic reticulum03 medical and health sciencescDNA complementary DNAInternal medicineALT alanine aminotransferaseGastroenterologiInternal MedicinemedicineNAFL non-alcoholic fatty liverALGORITHMFIB-4 fibrosis-4education030304 developmental biologyPCA principal component analysisScience & TechnologyGastroenterology & HepatologyHepatologybusiness.industryBiomarkerFC fold changemedicine.diseaseBiomarker; MicroRNA; Non-alcoholic fatty liver disease; Sequencingdigestive system diseasesFLIP fatty liver inhibition of progressionCt cycle thresholdSteatosisqPCR quantitative PCRbusinessNon-alcoholic fatty liver disease
researchProduct

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

2017

OBJECTIVES Non-invasive fibrosis scores are widely used to identify/exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). However, these scores were principally developed and validated in patients aged between 35 and 65 years of age. The objective of this study was to assess the effect of age on the performance of non-invasive fibrosis tests in NAFLD. METHODS Patients were recruited from European specialist hepatology clinics. The cohort was divided into five age-based groups: ≤35 (n=74), 36-45 (n=96), 46-55 (n=197), 56-64 (n=191), and ≥65 years (n=76), and the performance of the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio, fibrosis 4 (F…

MaleLiver CirrhosisPathologyBiopsyPredictive Value of TestAspartate AminotransferasesGastroenterology0302 clinical medicineFibrosisReference ValuesNon-alcoholic Fatty Liver DiseaseArea under curvePrevalenceMedicineReference ValueAge FactorConfoundingAge FactorsGastroenterologyAlanine TransaminaseFalse Positive ReactionMiddle Aged3. Good healthLiver030220 oncology & carcinogenesisPredictive value of testsArea Under Curve030211 gastroenterology & hepatologyFemaleLiver pathologyHumanAdultmedicine.medical_specialtyLiver Cirrhosi610 Medicine & healthdigestive system03 medical and health sciencesPredictive Value of TestsInternal medicineHumansFalse Positive ReactionsAspartate AminotransferasesAgedHepatologybusiness.industryPlatelet CountNon invasivenutritional and metabolic diseasesAspartate AminotransferaseHepatologymedicine.diseaseFibrosisdigestive system diseasesFatty LiverROC CurveHuman medicinebusinessBiomarkersThe American Journal of Gastroenterology
researchProduct